News Summary:
On February 19, 2026, Cytiva, a Danaher operating company, unified its MedTech and BioTech regulatory divisions with Veeva RIM. This integration addressed challenges, including decentralized data management and a split regulatory workforce, that emerged following its 2023 portfolio integration. Previously, on February 15, Cytiva highlighted its Whatman lab filtration range, which features glass and quartz microfiber filter materials for applications such as nucleic acid extraction and environmental monitoring, noting their variation in particle retention, thickness, and porosity. This activity occurred as the broader biotech and biomanufacturing sectors experienced significant developments. On February 5, mass spectrometry underwent a renaissance in these fields, driven by diversifying drug modalities and increasing analytical burdens. Concurrently, on February 4, allogeneic natural killer (NK) cells gained momentum as a cancer immunotherapy platform, potentially offering "off-the-shelf" availability. Earlier, on February 3, Cytiva released an application note detailing tests on its Cadence™ inline concentrator (ILC) modules, utilizing Omega™ and Delta membranes, for volume reduction during 24-hour continuous feed processing of human immunoglobulin G (IgG) for purification.
Subscribe for full access to Cytiva's products in full detail 
